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Meningococcal disease caused by Neisseria meningitidis sero-
group B is a public health concern even in developed countries. 
Despite glycoconjugate vaccines against the other invasive sero-
groups (A, C, W135, Y) are already available and successfully 
introduced in many countries, no vaccine is currently in use for 
prevention of serogroup B meningitis. 
A protein based, multicomponent vaccine (4CMenB) has been 
developed and proposed for prevention of invasive serogroup B 
meningococcal disease (MenB). This novel vaccine has been tested 
in clinical trials and shown to be well tolerated and immunogenic, 
inducing bactericidal antibodies in infants, adolescents and adults. 
The high level of genetic and antigenic variability observed in 
MenB clinical isolates, requires a suitable method to assess the 
ability of the 4CMenB vaccine to cover genetically diverse menig-
ococcal strains and to estimate the potential public health impact. 
To this purpose the Meningococcal Antigen Typing System 
(MATS) has been developed and recently described. This method 
provides a quick and reproducible tool to estimate the level of 
expression and immunoreactivity of each of the vaccine antigens, 
in any meningococcal isolate, and it is related to the likelihood 
that the isolate will be killed by sera from immunized subjects. 
A multi-laboratory study involving several European countries, 
demonstrates that the 4CMenB has the potential to protect against 
a significant proportion of menB strains circulating in Europe.
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Summary
Introduction
Neisseria meningitidis is an encapsulated, Gram-neg-
ative bacterium, obligate human commensal and occa-
sional pathogen. In the majority of cases it colonizes the 
upper respiratory tract with no consequence, spreading 
directly from host to host. Carriage prevalence in Eu-
rope and in other countries with a similar epidemio-
logic pattern is low in young children, reaches the peak 
in 19 years old (23.7%) and decreases in adults [1, 2]. 
In a small number of cases it causes invasive disease, 
entering the bloodstream, crossing the blood-brain bar-
rier and causing sepsis and meningitis. Young children 
under 5 years are the most exposed age group to inva-
sive disease, as this age group shows the highest inci-
dence [3]. 
N. meningitidis strains have been divided into 13 se-
rogroups based on differences in the capsular polysac-
charide structures. Five of these serogroups (A, B, C, 
Y, W 135) cause the majority of endemic, epidemic and 
pandemic outbreaks of meningitis. Serogroups are dis-
tributed worldwide: serogroup A has been associated 
with epidemic outbreaks in sub-Saharan Africa, and to 
a lesser extent in Asia; serogroup B is the main cause 
of prolonged outbreaks in Europe, America and New 
Zealand; serogroup C strains are spread worldwide and 
caused local outbreaks in Western Europe and North 
America, mainly in adolescents and young adults [4]. In 
the last twenty years, serogroup Y has emerged as an 
important cause of disease in North America and Israel 
while local outbreaks of serogroup X strains have been 
reported in sub-Saharan Africa [5, 6].
Capsular polysaccharide (CPS)-based vaccines against 
meningococcal serogroups A, C, Y & W135 have been 
available for several years, and more effective con-
jugated vaccines have been introduced, in which CPS 
components are conjugated to carrier proteins such as 
CRM197, a non-toxic mutant of the diphtheria toxin [7]. 
MenACWY-CRM has been shown to be immunogenic 
in all age groups, including infants [8]. The introduc-
tion of routine vaccination programs have significantly 
reduced the incidence of serogroup C disease in many 
countries including Italy, UK, Australia, Brazil and Ar-
gentina [9].
Despite the successful prevention campaign against 
meningococcal disease, serogroup B meningitis is still 
an important concern in industrialized countries. For 
example, approximately 90% of the cases in England 
and Wales are currently due to serogroup B meningo-
cocci [10] while the overall proportion of serogroup B 
cases has been 71% among 9615 cases reported in Eu-
rope during 2008-9 [11].
The group B polysaccharide is poorly immunogenic, even 
when conjugated to a carrier protein; furthermore, the 
capsular polysaccharide chemical composition, which is 
similar to glycosilated structures in human cells, could 
facilitate the onset of auto-immune disease [12, 13]. 
Many efforts have been made over the last years to find 
broadly protective antigens against group B meningo-
cocci, but the high sequence variability of candidate pro-
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tein antigens has been a serious challenge for vaccine 
developers [6]. Outer membrane vesicle (OMV) protein-
based vaccines have been developed based on the ability 
of meningococcus to produce and release vesicles com-
posed of outer membrane proteins, lipids and periplas-
mic components. The OMV vaccines used in Norway, 
Cuba, Chile and New Zealand to address local epidemic 
outbreaks have all been prepared from the wild-type 
strains causing the outbreaks [14-17]. OMV-based vac-
cines induce antibodies in all age groups and although 
effective in protecting against epidemic disease, they 
generally elicit protection only against the homologous 
strain [18]. This is mainly due to the high sequence vari-
ability of the PorA antigen, which is the immunodomi-
nant and most abundant membrane protein. Based on 
these observations, each single OMV vaccine is not ap-
plicable for universal use and effective menB vaccines 
based on different surface exposed proteins have there-
fore been investigated. 
4CMenB vaccine
The introduction of reverse vaccinology has changed the 
concept of vaccine development facilitating the identi-
fication of promising candidate antigens, starting from 
genome sequence as an alternative to microbial culture 
purifications [19]. The whole genome sequence of a 
virulent strain (MC58) was used to identify candidate 
vaccine antigens, among the potential surface–exposed 
proteins. Using this approach, 28 Genome-derived Neis-
seria Antigens (GNA) were found to induce bactericidal 
antibodies [20]. 
The antigens selected by reverse vaccinology have been 
further investigated by means of Serum Bactericidal 
Assay (SBA) and passive protection assays in animal 
models for their abilty to induce broad protection. Three 
surface exposed proteins were selected as components 
of the vaccine: GNA1870 lately named factor H bind-
ing protein [fHbp; 21-22-23], GNA2132 lately named 
Neisserial Heparin Binding Antigen [NHBA; 24] and 
GNA1994 lately named Neisseria adhesin A [NadA; 25]. 
To facilitate large-scale manufacturing and to increase 
immunogenicity, two antigens were fused with menin-
gococcal accessory proteins GNA1030 and GNA2091 
to create the fusion protein antigens GNA2091-fHbp 
and NHBA-GNA1030. These two fusions were com-
bined with NadA and formulated with aluminium hy-
droxide to produce a novel recombinant MenB vaccine 
(rMenB). The sera obtained by immunizing mice with 
rMenB vaccine were tested by SBA against a panel of 85 
globally distributed menB isolates and showed killing of 
78% of the strain [26].
The rMenB vaccine has been also tested in Phase 
I and Phase II clinical trials alone or in combination 
with OMVs derived from the New Zealand strain NZ 
98/254 [27, 28], expressing PorA serosubtype P1.4 
(rMenB + OMV) which was shown to be safe and ef-
ficacious in controlling a clonal meningococcal sero-
group B epidemic in New Zealand [17]. The final vac-
cine formulation, which includes also OMVs (Fig. 1), 
was named four component meningococcal serogroup 
B vaccine (4CMenB). The reason for using all the three 
main antigens combined with OMV, was to provide a 
broader strain coverage and reduce the risk of escape 
mutants. 
Vaccine immunogenicity 
Assessing the efficacy of a protein-based vaccine for a 
large panel of strains representative of the global MenB 
disease burden is a serious challenge for both vaccine 
manufacturers and regulatory agencies. Human comple-
ment (hSBA) measures the ability of human sera anti-
bodies to kill bacteria by activating the classical comple-
ment pathway. Acquisition of a 1:4 SBA titer threshold 
measured using hSBA has been acknowleged as the ap-
propriate correlate of protection to assess the efficacy of 
candidate vaccine [29]. 
However, hSBA is labor intensive and requires ade-
quate volumes of serum sample, a particularly limiting 
parameter in infants. Therefore, the testing of numer-
ous strains by numerous subjects quickly becomes un-
tenable. The hSBA is nevertheless essential to screen 
potential human complement sources lacking endog-
enous anti-meningococcal antibodies against the test 
isolates. Moreover, a high number of assays can be 
required to establish cross protection of bactericidal 
antibodies across antigens variants or subvariants, and 
to understand whether observed differences in SBA 
are due to sequence variability or to the level of pro-
tein expression [30]. When a SBA assay is performed 
using immune sera from humans vaccinated with the 
4CMenB vaccine, the assay will not discriminate be-
tween the effects of different antigens and bacteria are 
killed by combinations of antibod-
ies elicited by multiple antigens. 
In order to assess the immuno-
genicity of each of the 4CMenB 
vaccine components, it is neces-
sary to measure antigen-specific 
bactericidal antibodies against N. 
meningitidis strains in which kill-
ing is directed primarily against 
a single antigen represented in 
4CMenB [31]. Using this ap-
proach, a minimal strain panel can 
be used to assess whether a sero-
Fig. 1. 4CmenB vaccine composition.
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response to the vaccine has occurred. Sera from sub-
jects belonging to different age groups immunized with 
4CMenB have been tested in the bactericidal assay with 
human complement to measure vaccine specific bacte-
ricidal responses using this panel of strains. The data 
showed that most subjects elicited bactericidal antibod-
ies against each of the major antigens, demonstrating 
that each component is able to induce protective bacte-
ricidal response in humans [27, 28, 32-35].
However, assessing the potential strain coverage of 
4CMenB is a challenge due to heterogeneity of vaccine 
antigens across MenB strains which can impact anti-
body-mediated complement-dependent killing.
Conventional typing methods used for N. meningitidis, 
such as serotyping and serosubtyping or multilocus se-
quence typing, are not necessarily relevant to predict 
bactericidal killing in the SBA assay and to estimate 
4CMenB vaccine strain coverage.
A quick and reproducible tool to estimate 
vaccine coverage
Laboratory tests intended as a surrogate of the serum 
bactericidal assay should be able to relate levels of anti-
gen expression and sequence similarity to the ability of 
vaccine-elicited antibodies to kill bacteria. A robust esti-
mation of strain coverage would thus require a bridge be-
tween the observed immunity against a restricted strain 
panel in clinical trials to protection from broadly diverse 
endemic MenB strains. To address this, the Meningo-
coccal Antigen Typing System (MATS), a rapid and re-
producible binding assay, was developed to predict the 
susceptibility of MenB isolates to vaccine-elicited bac-
tericidal killing. MATS is capable of measuring both the 
level of sequence relatedness and expression of antigens 
on a given meningococcal strain [36].
MATS combines modified ELISA assays to measure the 
antigenic cross-reactivity and expression of fHbp, NadA 
and NHBA on bacterial lysates and sequencing of the 
dominant OMV immunogen. A strain that matches the 
PorA serosubtype (PorA 1.4) is considered covered by 
the vaccine. 
The MATS ELISA has been previously described (Fig 2). 
Antigenic reactivity and level of expression are mea-
sured in test samples by capturing the antigens of lysed 
bacterial suspensions in 3 different ELISA plates, coated 
with polyclonal rabbit antibodies raised against the vac-
cine components fHbp, NHBA, and NadA. To evaluate 
whether the relative antigen content measured by MATS 
correlates with bactericidal activity, 57 serogroup B iso-
lates with known antigen genotypes and MATS values 
have been tested by hSBA using pooled sera from in-
fants immunized with the 4CMenB. 
Fig. 2. schematic representation of the mats elisa method [36]: bacteria from overnight cultures on agar Chocolate plates, are suspended 
in mueller-hinton broth; lysed with a detergent (empigenBB 5%) added to a final volume of 1/11 and inactivated for 1 hr at 45°C in water 
bath; bacterial lysates are added to three different elisa microwell plates coated with polyclonal rabbit antibodies raised against the single 
vaccine components fhbp, NhBa, and Nada, the antigens are captured from the suspension to the plate; plates are then incubated with 
biotinylated rabbit polyclonal antibodies against each of the antigens for 1 hour at 37°C, washed, incubated with streptavidin-hrp and 
developed with the Opd substrate; relative potency is calculated by interpolating the regression curve of the unknown sample vs. that of 
a reference strain added to each plate.
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By comparing the MATS relative potency values with 
SBA results, threshold values (positive bactericidal 
thresholds, PBTs) were defined for each of the three an-
tigens, specifically 2.1, 29.4 and 0.9% for fHbp, NHBA 
and NadA respectively. A strain with a relative potency 
above the PBT for at least one of the 3 antigens is pre-
dicted to be killed in SBA at a ≥ 80% probability [36]. 
The multi laboratory study
The MATS method has been transferred to five Euro-
pean reference laboratories: Health Protection Agency 
(HPA) for England & Wales, Norwegian Institute of 
Public Health (NIPH) in Norway, Institut Pasteur in 
France, Wurzburg University in Germany, Istituto Su-
periore di Sanità in Italy; Center for Disease Control 
(CDC) for USA. An inter-laboratory comparison study, 
among these six laboratories and the Novartis laboratory 
in Siena, has been run by comparing repeated testing of 
a selected panel of strains. MATS proved to be highly 
reproducible and comparable across the seven labora-
tories [Plykaytis et al. submitted] and the method has 
been subsequently transferred in additional laboratories 
in Europe and Australia. 
MATS was then performed by the reference laboratories 
on their own collection of MenB isolates, collected during 
the epidemiologic period July 2007 – June 2008. Strain 
coverage was then defined as the proportion of strains 
having at least one vaccine antigen above the PBT (NadA, 
NHBA, or fHbp) or the PorA serosubtype 1.4 [36]. Re-
gional strain coverage based on data provided by the five 
European laboratories demonstrates that the 4CMenB 
vaccine can be broadly protective across Europe. 
To provide more global information about the vaccine 
antigens distribution and vaccine strains coverage, data-
sets from other European countries, North and South 
America and Australia are already available or soon to 
be completed.
As the introduction of vaccine will have some impact on 
the bacterial population, the reference laboratories will 
use MATS also after the 4CMenB introduction. This 
would allow the monitoring of strains not covered by 
the vaccine, or the emergence of escape mutants.
Conclusions
The hSBA is the only correlate of protection accepted 
thus far to assess the efficacy for a multi-components 
protein-based MenB vaccine [29]. Since a large number 
of SBA tests are required because of the high genetic 
variability observed in MenB isolates, the need to com-
bine SBA with other immunologic and genetic data has 
been raised [12, 37].
The Meningococcal Antigen Typing System provides 
a useful and reproducible tool to estimate the potential 
coverage of 4CMenB recombinant vaccine. A large part 
of the isolates circulating in Europe are predicted to be 
killed by the 4CMenB vaccine. Since PTBs have been 
established using infant immune sera, the coverage es-
timate could be potentially higher for adolescents and 
adults. Furthermore, the proportion of killed strains is 
generally increased when a collection is populated by 
those that express more than one antigen above the 
PBT [36], suggesting that antibodies against multiple 
antigens elicit a cooperative effect. The MATS assay 
may be used after the introduction of the vaccine, in or-
der to monitor evolution in meningococcal population 
structure.
The introduction 4CMenB vaccine could have an impact 
also on other meningococcal serogroups, as the antigens 
in the vaccine are not exclusively expressed in MenB 
strains but also present in other serogroups. Measuring 
the level of expression and variability of 4CMenB vac-
cine antigens for invasive meningococcal serogroups 
other than B will provide information about the impact 
of vaccine on other meningococcal serogroups.
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